Part 2: Pre-existing Immunity Against AAV Serotypes and What This Means for Hemophilia Gene Therapy Clinical Trials

Part 2: Pre-existing Immunity Against AAV Serotypes and What This Means for Hemophilia Gene Therapy Clinical Trials

Listen as Drs. Steven Pipe and Nigel Key discuss the evolving science and latest clinical advancements in gene therapy in hemophilia.

Steven Pipe, MD

Steven Pipe, MD
University of Michigan
Ann Arbor, Michigan, USA

Steven Pipe, MD is Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan, Ann Arbor, Michigan, USA. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding, thrombotic disorders, and congenital vascular anomalies. Dr. Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia, including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. Dr. Pipe has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and currently as Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation.

Nigel Key, MB, ChB. FRCP,

Nigel Key, MB, ChB, FRCP
University of North Carolina School of Medicine
Chapel Hill, North Carolina, USA

Nigel Key, MB, ChB, FRCP, is an adult hematologist specializing in non-malignant hematologic disorders, particularly those affecting blood coagulation. Dr. Key is the Harold R. Roberts Distinguished Professor, Chief of the Section of Hematology in the Division of Hematology/Oncology, and Director of the UNC Hemophilia and Thrombosis Center. A graduate of the University of St Andrews and the University of Manchester Medical School (both in the United Kingdom), Dr. Key received his early training in internal medicine in Bath and hematology in Oxford, UK. Following 15 years on the Hematology/Oncology faculty at the University of Minnesota, Dr Key was recruited to UNC in 2005. His clinical interests include the diagnosis and management of bleeding disorders including hemophilia and von Willebrand disease, as well as arterial and venous thromboembolic disorders. Dr. Key has authored well over 100 peer-reviewed articles, approximately 20 book chapters, and is co-editor of a popular textbook on disorders of bleeding and clotting.

Image

Please enable the javascript to submit this form

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., and Spark Therapeutics

Essential SSL